Predictive Elements of Trauma and Its After-effects: Importance of the Quality of Neurobiological Response to Stress

NCT ID: NCT04530214

Last Updated: 2023-04-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-04

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The neurobiological response to stress is an adaptive response allowing us to cope with the multiple aggressions of daily life. This response orchestrates the body's systemic reaction. The intensity of response to stress can modify the body's functioning, which implies a variety of fields where biomarkers may be isolated: immunity, psychology, neurophysiology, integrative physiology. When stress is too intense or prolonged, response to stress may become misfitted and deleterious.

This study is based on the hypothesis that a severe physical or psychological trauma is associated with an intense and misfitted stress that is responsible from an undue immuno-inflammatory activation (through sympathetic activation). The result is a subinvasive state of systemic and tissue inflammation (low-noise inflammation), responsible for the mid-term deleterious consequences of the traumatic event.

The objective of this study is to understand how the dysregulation of intense stress simultaneously generates an initial pathological state and an alteration of mid-term evolution (which is considered as a poor prognosis and/or as responsible for after-effects).

The investigators wish to identify relevant biomarkers of the mechanisms activated during intense stress and influencing the immuno-inflammatory and epigenetic spheres with deleterious consequences on physiological and psychological functions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood collection

Blood collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)

Intervention Type OTHER

Saliva collection

Saliva collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)

Intervention Type OTHER

Electrocardiography (ECG)

Electrocardiography (ECG) at enrollment (24-72h following surgery) and at Visit 1 (45-60 days following surgery) to assess heart rate variability

Intervention Type OTHER

Questionnaires

Mental health assessment through questionnaires at enrollment (24-72h following surgery), at Visit 1 (45-60 days following surgery), at Visit 2 (7 months following surgery) and at Visit 3 (12 months following surgery)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fracture of the upper end of the femur
* Cognitive state allowing the understanding of questionnaires

Exclusion Criteria

* Traumatic Brain Injury
* Chronic inflammatory or immune pathologies
* On anticoagulants
* On neuroleptic or antidepressant treatment
* Pathology or health condition not allowing 1-year survival
Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Direction Centrale du Service de Santé des Armées

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Pellegrin

Bordeaux, , France

Site Status NOT_YET_RECRUITING

Hôpital d'Instruction des Armées Percy

Clamart, , France

Site Status NOT_YET_RECRUITING

Hôpital d'Instruction des Armées Bégin

Saint-Mandé, , France

Site Status NOT_YET_RECRUITING

Hôpital d'Instruction des Armées Sainte-Anne

Toulon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anaïs DUFFAUD

Role: CONTACT

178651315 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Cédric GIL-JARDINE, MD

Role: primary

Sylvain MARTINEZ, MD

Role: primary

Diane COMMANDEUR, MD

Role: primary

Julien BORDES, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-A01811-56

Identifier Type: OTHER

Identifier Source: secondary_id

2018PPRC30

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.